Table 5.
Comparative outcomes in patients with predicted HFpEF and type 2 diabetes initiating SGLT2i vs. sitagliptin under 365-day intention-to-treat follow-up
| Exposure group | Unweighted | Propensity score weighted | ||
|---|---|---|---|---|
| SGLT2i | Sitagliptin | SGLT2i | Sitagliptin | |
| Sample size | 14 708 | 39 529 | 14 641 | 39 198 |
| Primary composite endpoint of all-cause mortality or worsening HF | ||||
| Total events | 1045 | 5712 | 1042 | 3887 |
| Follow-up, person-years | 10 772 | 31 175 | 10 743 | 28 776 |
| Incidence rate (95% CI)/100 person-years | 9.7 (9.1–10.3) | 18.3 (17.9–18.8) | 9.7 (9.1–10.3) | 13.5 (13.1–13.9) |
| HR (95% CI) | 0.52 (0.49–0.56) | Ref | 0.72 (0.66–0.78) | Ref |
| Single components of the primary composite endpoint | ||||
| All-cause mortality | ||||
| Total events | 566 | 4191 | 566 | 2199 |
| Follow-up, person-years | 11 218 | 33 860 | 11 188 | 30 561 |
| Incidence rate (95% CI)/100 person-years | 5.0 (4.6–5.5) | 12.4 (12.0–12.8) | 5.1 (4.7–5.5) | 7.2 (7.0–7.5) |
| HR (95% CI) | 0.41 (0.37–0.45) | Ref | 0.70 (0.63–0.79) | Ref |
| Hospitalization for heart failure | ||||
| Total events | 643 | 4222 | 641 | 2689 |
| Follow-up, person-years | 10 956 | 31 942 | 10 926 | 29 374 |
| Incidence rate (95% CI)/100 person-years | 5.9 (5.4–6.3) | 13.2 (12.8–13.6) | 5.9 (5.4–6.3) | 9.2 (8.8–9.5) |
| HR (95% CI) | 0.44 (0.40–0.48) | Ref | 0.64 (0.58–0.71) | Ref |
| Urgent visit requiring intravenous diuretics | ||||
| Total events | 520 | 2311 | 519 | 1761 |
| Follow-up, person-years | 10 994 | 32 773 | 10 964 | 29 743 |
| Incidence rate (95% CI)/100 person-years | 4.7 (4.3–5.2) | 7.1 (6.8–7.3) | 4.7 (4.3–5.2) | 5.9 (5.6–6.2) |
| HR (95% CI) | 0.66 (0.60–0.73) | Ref | 0.80 (0.71–0.90) | Ref |
CI, confidence interval; HF, heart failure; HR, hazard ratio; SGLT2i, sodium–glucose cotransporter 2 inhibitors.